Cargando…

p53 Family in Resistance to Targeted Therapy of Melanoma

Metastatic melanoma is one of the most aggressive tumors, with frequent mutations affecting components of the MAPK pathway, mainly protein kinase BRAF. Despite promising initial response to BRAF inhibitors, melanoma progresses due to development of resistance. In addition to frequent reactivation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlašić, Ignacija, Horvat, Anđela, Tadijan, Ana, Slade, Neda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820688/ https://www.ncbi.nlm.nih.gov/pubmed/36613518 http://dx.doi.org/10.3390/ijms24010065

Ejemplares similares

p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies
por: Horvat, Anđela, et al.
Publicado: (2021)

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance
por: Radić, Martina, et al.
Publicado: (2022)

Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness
por: Tadijan, Ana, et al.
Publicado: (2021)

Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions
por: Tadijan, Ana, et al.
Publicado: (2022)

Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines
por: Ozretić, Petar, et al.
Publicado: (2019)

Role of p53 in breast cancer progression: An insight into p53 targeted therapy
por: Marvalim, Charlie, et al.
Publicado: (2023)

Targeted Therapy in Melanoma and Mechanisms of Resistance
por: Czarnecka, Anna M., et al.
Publicado: (2020)

Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021)

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance
por: Loureiro, Joana B., et al.
Publicado: (2021)

Bacillus subtilis RecA and its accessory factors, RecF, RecO, RecR and RecX, are required for spore resistance to DNA double-strand break
por: Vlašić, Ignacija, et al.
Publicado: (2014)

The Development of p53-Targeted Therapies for Human Cancers
por: Lu, Yier, et al.
Publicado: (2023)

Neurotoxic Effect of Flavonol Myricetin in the Presence of Excess Copper
por: Sadžak, Anja, et al.
Publicado: (2021)

The role of p53 in cancer drug resistance and targeted chemotherapy
por: Hientz, Karin, et al.
Publicado: (2016)

STAT3 and p53: Dual Target for Cancer Therapy
por: Pham, Thu-Huyen, et al.
Publicado: (2020)

The Tumor Suppressor p53 in Mucosal Melanoma of the Head and Neck
por: Fritsche, Marie Kristin, et al.
Publicado: (2017)

MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017)

The p53 family reaches the final frontier: the variegated regulation of the dark matter of the genome by the p53 family in cancer
por: Napoli, Marco, et al.
Publicado: (2020)

p53 targets TSPAN8 to prevent invasion in melanoma cells
por: Agaësse, G, et al.
Publicado: (2017)

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
por: Keller, Hilary R., et al.
Publicado: (2017)

Metabolic Regulation by p53 Family Members
por: Berkers, Celia R., et al.
Publicado: (2013)

Targeting p53 pathways: mechanisms, structures, and advances in therapy
por: Wang, Haolan, et al.
Publicado: (2023)

The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy
por: Nakamura, Mitsuhiro, et al.
Publicado: (2019)

Targeting mutant p53 for cancer therapy: direct and indirect strategies
por: Hu, Jiahao, et al.
Publicado: (2021)

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
por: Rubanov, Andrey, et al.
Publicado: (2022)

Structural and Drug Targeting Insights on Mutant p53
por: Gomes, Ana Sara, et al.
Publicado: (2021)

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
por: Falcone, Italia, et al.
Publicado: (2020)

Targeted therapy in melanoma
por: Tawbi, Hussein, et al.
Publicado: (2009)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
por: Pandya, Pinakin, et al.
Publicado: (2022)

DNA repair and aging: the impact of the p53 family
por: Nicolai, Sara, et al.
Publicado: (2015)

Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research
por: Levine, Arnold J.
Publicado: (2022)

Targeting mutant p53 for cancer therapy
por: Oren, Moshe, et al.
Publicado: (2016)

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
por: Gallagher, Stuart J, et al.
Publicado: (2015)

Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
por: Pizzimenti, Stefania, et al.
Publicado: (2021)

Melanogenesis and the Targeted Therapy of Melanoma
por: Li, Cang, et al.
Publicado: (2022)

Census and evaluation of p53 target genes
por: Fischer, M
Publicado: (2017)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Dominant effects of Δ40p53 on p53 function and melanoma cell fate
por: Takahashi, Rie, et al.
Publicado: (2013)

Emerging Roles of p53 Family Members in Glucose Metabolism
por: Itahana, Yoko, et al.
Publicado: (2018)

New Insights in Thyroid Cancer and p53 Family Proteins
por: Manzella, Livia, et al.
Publicado: (2017)

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
por: Bang, Scott, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_82ppk6okvr873im3nm21q3ktf7